FibroBiologics Inc. has announced that it has fully repaid all outstanding amounts under its convertible promissory notes previously issued to YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global. The repayment eliminates further dilution from potential conversions of these notes into common stock. With the debt now cleared, FibroBiologics' balance sheet is strengthened, allowing the company to focus on advancing its clinical programs. The Standby Equity Purchase Agreement with Yorkville remains in place, permitting the company to sell up to an additional $10 million of its common stock at its discretion through December 2026, subject to certain conditions.